title: Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study.
abstract: BACKGROUND
  Encapsulating peritoneal sclerosis (EPS) is a serious complication of peritoneal dialysis (PD) with an increasing incidence. There is no clear consensus on the treatment of EPS, but anecdotal reports indicate improvement in EPS patients treated with tamoxifen. At present, there is no evidence for the effect of tamoxifen treatment in EPS patients. This study investigates the effect of treatment with tamoxifen on survival in EPS patients.
  
  
  METHODS
  This study is a retrospective analysis of survival in EPS patients as part of the Dutch multicentre EPS study in the period January 1996 to July 2007. Sixty-three patients with severe EPS were followed up until August 2008. Demographic, patient and PD-related variables of EPS patients were investigated. Patients treated with tamoxifen were compared to patients not treated with tamoxifen. Survival was analysed with multivariate Cox regression analysis.
  
  
  RESULTS
  Twenty-four patients were treated with tamoxifen, and 39 were not treated with tamoxifen. The clinical and demographic characteristics were similar for the tamoxifen-treated and non-treated groups. The mortality rate was significantly lower in tamoxifen-treated patients compared to EPS patients not treated with tamoxifen (45.8% vs 74.4%, P=0.03). Survival in tamoxifen-treated patients, adjusted for calendar time, age, use of corticosteroids, presence of functioning transplantation, use of parental nutrition and centre influences was longer in comparison to not-treated patients (HR 0.39, P=0.056).
  
  
  CONCLUSIONS
  Tamoxifen treatment in EPS patients is associated with lower mortality and shows a trend to an increased multivariate-adjusted survival. This supports additional use of tamoxifen to treat patients with severe EPS.
authors.affiliation: Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands. m.r.korte@asz.nl
authors.forename: Mario R
authors.initials: MR
authors.lastname: Korte
authors.forename: Marien W
authors.initials: MW
authors.lastname: Fieren
authors.forename: Denise E
authors.initials: DE
authors.lastname: Sampimon
authors.forename: Hester F
authors.initials: HF
authors.lastname: Lingsma
authors.forename: Willem
authors.initials: W
authors.lastname: Weimar
authors.forename: Michiel G H
authors.initials: MG
authors.lastname: Betjes
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D056627:Peritoneal Fibrosis / Q000188:drug therapy* / Q000209:etiology; D012189:Retrospective Studies; D016019:Survival Analysis; D013629:Tamoxifen
chemical_list: D000893:Anti-Inflammatory Agents; D013629:Tamoxifen